Pharmacology of drugs of abuse

Obstetrics and Gynecology Clinics of North America

Volumn 30, Issue 3, 2003, Pages 501-522

  Reynolds, Eric W ^a   Bada, Henrietta S ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMPHETAMINE DERIVATIVE; CANNABIS; DIAMORPHINE; DOPAMINE; FLUOXETINE; HYDROCODONE; MORPHINE; NICOTINE; NORADRENALIN; OPIATE; PSYCHEDELIC AGENT; SEROTONIN;

DOPAMINERGIC SYSTEM; DRUG ABUSE; DRUG DEPENDENCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TOLERANCE; ENVIRONMENTAL FACTOR; GENETIC PREDISPOSITION; HUMAN; MESOLIMBIC DOPAMINERGIC SYSTEM; NEUROTRANSMISSION; PATHOPHYSIOLOGY; POSTSYNAPTIC MEMBRANE; PREGNANCY; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM; SEX DIFFERENCE;

EID: 0242656351     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8545(03)00078-0     Document Type: Review

References (82)

1. National Household Survey on Drug Abuse (NHSDA). Rockville, MD: Office of Applied Statistics; 2001 & 2002. Available at: http://www.DrugAbuseStatistics.SAMHSA.gov.
2. Blumenthal SJ. Women and substance abuse: a new national focus. In: Wetherington CL, Roman AB, editors. Drug addiction research and the health of women. Rockville, MD: US Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse; 1998. p. 13-31.
3. Bada HS, Bauer CR, Shankaran S, Lester B, Wright LL, Das A, et al. Central and autonomic system signs with in utero drug exposure. Arch Dis Child Fetal Neonatal Ed 2002;87:F106-12.
4. Bauer CR, Shankaran S, Bada HS, Lester B, Wright LL, Krause-Steinrauf H, et al. The Maternal Lifestyle Study: drug exposure during pregnancy and short-term maternal outcomes. Am J Obstet Gynecol 2002;186:487-95.
5. Bauer CR. Perinatal effects of prenatal drug exposure. Neonatal aspects. Clin Perinatol 1999;26:87-106.
6. Kandel DB, Warner LA, Kessler RC. The epidemiology of substance abuse and dependence among women. In: Wetherington CL, Roman AB, editors. Drug addiction research and the health of women. Rockville, MD: US Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse; 1998. p. 105-30.
7. Lynch WJ, Roth ME, Carroll ME. Biological basis of sex differences in drug abuse: preclinical and clinical studies. Psychopharmacology (Berl) 2002;164:121-37.
8. Koob GF. Drug addiction: the yin and yang of hedonic homeostasis. Neuron 1996;16:893-6.
9. Kreek MJ, Koob GF. Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend 1998;51:23-47.
10. Nestler EJ. Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2001;2:119-28.
11. Nestler EJ, Aghajanian GK. Molecular and cellular basis of addiction. Science 1997;278:58-63.
12. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mul opioid receptor mechanism. Science 1997;276:2048-50.
13. Malanga 3rd CJ, Kosofsky BE. Mechanisms of action of drugs of abuse on the developing fetal brain. Clin Perinatol 1999;26:17-37 [v-vi].
14. Kelz MB, Nestler EJ. deltaFosB: a molecular switch underlying long-term neural plasticity. Curr Opin Neurol 2000;13(6):715-20.
15. Kelz MB, Chen J, Carlezon Jr WA, Whisler K, Gilden L, Beckmann AM, et al. Expression of the transcription factor deltaFosB in the brain controls sensitivity to cocaine. Nature 1999;401:272-6.
16. Atkins JB, Chlan-Fourney J, Nye HE, Hiroi N, Carlezon Jr WA, Nestler EJ. Region-specific induction of deltaFosB by repeated administration of typical versus atypical antipsychotic drugs. Synapse 1999;33:118-28.
17. Nestler EJ, Barrot M, Self DW. DeltaFosB: a sustained molecular switch for addiction. Proc Natl Acad Sci U S A 2001;98:11042-6.
18. De Vries TJ, Shippenberg TS. Neural systems underlying opiate addiction. J Neurosci 2002;22:3321-5.
19. Akil H, Owens C, Gutstein H, Taylor L, Curran E, Watson S. Endogenous opioids: overview and current issues. Drug Alcohol Depend 1998;51:127-40.
20. Shippenberg TS, Elmer GI. The neurobiology of opiate reinforcement. Crit Rev Neurobiol 1998;12:267-303.
21. Groenewegen HJ, Wright CI, Beijer AV. The nucleus accumbens: gateway for limbic structures to reach the motor system? Prog Brain Res 1996;107:485-511.
22. Chang JY, Janak PH, Woodward DJ. Comparison of mesocorticolimbic neuronal responses during cocaine and heroin self-administration in freely moving rats. J Neurosci 1998;18:3098-115.
23. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 1999;20:287-94.
24. Bonci A, Williams JT. Increased probability of GABA release during withdrawal from morphine. J Neurosci 1997;17:796-803.
25. Druhan JP, Walters CL, Aston-Jones G. Behavioral activation induced by D(2)-like receptor stimulation during opiate withdrawal. J Pharmacol Exp Ther 2000;294:531-8.
26. Stewart J. Pathways to relapse: the neurobiology of drug- and stress-induced relapse to drug-taking. J Psychiatry Neurosci 2000;25:125-36.
27. Benziger DP, Miotto J, Grandy RP, Thomas GB, Swanton RE, Fitzmartin RD. A pharmacokinetic/pharmacodynamic study of controlled-release oxycodone. J Pain Symptom Manage 1997;13:75-82.
28. Oyler JM, Cone EJ, Joseph Jr RE, Huestis MA. Identification of hydrocodone in human urine following controlled codeine administration. J Anal Toxicol 2000;24:530-5.
29. Lauterbach EC. Hiccup and apparent myoclonus after hydrocodone: review of the opiate-related hiccup and myoclonus literature. Clin Neuropharmacol 1999;22:87-92.
30. Fries DS. Opioid analgesics. In: Williams DA, Lemke TL, editors. Foye's principles of medicinal chemistry. Baltimore (MD): Lippincott Williams and Wilkins; 2002. p. 453-79.
31. Dackis CA, O'Brien CP. Cocaine dependence: a disease of the brain's reward centers. J Subst Abuse Treat 2001;21:111-7.
32. Farrar HC, Kearns GL. Cocaine: clinical pharmacology and toxicology. J Pediatr 1989;115:665-75.
33. Reith ME, Meisler BE, Sershen H, Lajtha A. Structural requirements for cocaine congeners to interact with dopamine and serotonin uptake sites in mouse brain and to induce stereotyped behavior. Biochem Pharmacol 1986;35:1123-9.
34. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987;237:1219-23.
35. Dolphin AC. G protein modulation of calcium currents in neurons. Annu Rev Physiol 1990;52:243-55.
36. Ranaldi R, Wise RA. Blockade of D1 dopamine receptors in the ventral tegmental area decreases cocaine reward: possible role for dendritically released dopamine. J Neurosci 2001;21:5841-6.
37. Glennon RA. Hallucinogens, stimulants and related drugs of abuse. In: Williams DA, Lemke TL, editors. Foye's principles of medicinal chemistry. Baltimore (MD): Lippincott Williams and Wilkins; 2002. p. 434-52.
38. White FJ, Kalivas PW. Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alcohol Depend 1998;51:141-53.
39. Hyman SE. Addiction to cocaine and amphetamine. Neuron 1996;16:901-4.
40. Seiden LS, Sabol KE, Ricaurte GA. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 1993;33:639-77.
41. Childers SR, Breivogel CS. Cannabis and endogenous cannabinoid systems. Drug Alcohol Depend 1998;51:173-87.
42. Pertwee RG. The central neuropharmacology of psychotropic cannabinoids. Pharmacol Ther 1988;36:189-261.
43. Herkenham M. Cannabinoid receptor localization in brain: relationship to motor and reward systems. Ann N Y Acad Sci 1992;654:19-32.
44. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001;410:822-5.
45. Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2001;22:565-72.
46. Hollister LE. Health aspects of cannabis. Pharmacol Rev 1986;38:1-20.
47. Maldonado R, Rodriguez de Fonseca F. Cannabinoid addiction: behavioral models and neural correlates. J Neurosci 2002;22:3326-31.
48. Romero J, Berrendero F, Manzanares J, Perez A, Corchero J, Fuentes JA, et al. Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol. Synapse 1998;30:298-308.
49. Rubino T, Patrini G, Parenti M, Massi P, Parolaro D. Chronic treatment with a synthetic cannabinoid CP-55,940 alters G-protein expression in the rat central nervous system. Brain Res Mol Brain Res 1997;44:191-7.
50. Aceto MD, Scates SM, Martin BB. Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2. Eur J Pharmacol 2001;416:75-81.
51. Picciotto MR, Corrigall WA. Neuronal systems underlying behaviors related to nicotine addiction: neural circuits and molecular genetics. J Neurosci 2002;22:3338-41.
52. Watkins SS, Koob GF, Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res 2000;2:19-37.
53. Lanca AJ, Adamson KL, Coen KM, Chow BL, Corrigall WA. The pedunculopontine tegmental nucleus and the role of cholinergic neurons in nicotine self-administration in the rat: a correlative neuroanatomical and behavioral study. Neuroscience 2000;96:735-42.
54. Fu Y, Matta SG, James TJ, Sharp BM. Nicotine-induced norepinephrine release in the rat amygdala and hippocampus is mediated through brainstem nicotinic cholinergic receptors. J Pharmacol Exp Ther 1998;284:1188-96
55. Benowitz N, Jacob P. Individual differences in nicotine kinetics and metabolism in humans. In: Rapaka RS, Chiang N, Martin BR, editors. Pharmacokinetics, metabolism and pharmaceutics of drugs of abuse. Rockville MD: National Institute on Drug Abuse; 1997. p. 48-64. NIDA Research Monograph 173.
56. Hilton ME. The demographic distribution of drinking patterns in 1984. Drug Alcohol Depend 1988;22:37-47.
57. Brodie MS, Shefner SA, Dunwiddie TV. Ethanol increases the firing rate of dopamine neurons of the rat ventral tegmental area in vitro. Brain Res 1990;508:65-9.
58. Budygin EA, Phillips PE, Wightman RM, Jones SR. Terminal effects of ethanol on dopamine dynamics in rat nucleus accumbens: an in vitro voltammetric study. Synapse 2001;42:77-9.
59. Diana M, Pistis M, Carboni S, Gessa GL, Rossetti ZL. Profound decrement of mesolimbic dopaminergic neuronal activity during ethanol withdrawal syndrome in rats: electrophysiological and biochemical evidence. Proc Natl Acad Sci U S A 1993;90:7966-9.
60. Weiss F, Parsons LH, Schulteis G, Hyytia P, Lorang MT, Bloom FE, et al. Ethanol self-administration restores withdrawal-associated deficiencies in accumbal dopamine and 5-hydroxytryptamine release in dependent rats. J Neurosci 1996;16:3474-85.
61. Rossetti ZL, Isola D, De Vry J, Fadda F. Effects of nimodipine on extracellular dopamine levels in the rat nucleus accumbens in ethanol withdrawal. Neuropharmacology 1999;38:1361-9.
62. Bailey CP, Andrews N, McKnight AT, Hughes J, Little HJ. Prolonged changes in neurochemistry of dopamine neurones after chronic ethanol consumption. Pharmacol Biochem Behav 2000;66:153-61.
63. Heinz A, Lichtenberg-Kraag B, Baum SS, Graf K, Kruger F, Dettling M, et al. Evidence for prolonged recovery of dopaminergic transmission after detoxification in alcoholics with poor treatment outcome. J Neural Transm Gen Sect 1995;102:149-57.
64. Olive MF, Koenig HN, Nannini MA, Hodge CW. Stimulation of endorphin neurotransmission in the nucleus accumbens by ethanol, cocaine, and amphetamine. J Neurosci 2001;21(RC184):1-5.
65. Gonzales RA, Weiss F. Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci 1998;18:10663-71.
66. Arnone M, Maruani J, Chaperon F, Thiebot MH, Poncelet M, Soubrie P, et al. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1997;132:104-6.
67. Kalra SP, Dube MG, Sahu A, Phelps CP, Kalra PS. Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. Proc Natl Acad Sci U S A 1991;88:10931-5.
68. Thiele TE, Koh MT, Pedrazzini T. Voluntary alcohol consumption is controlled via the neuropeptide Y Y1 receptor. J Neurosci 2002;22(RC208):1-6.
69. Pietrantoni M, Knuppel RA. Alcohol use in pregnancy. Clin Perinatol 1991;18:93-111.
70. Karan LD, Benowitz NL. Substance abuse: dependence and treatment. In: Carruthers SG, Hoffman BB, Melmon KL, Nierenberg DW, editors. Clinical Pharmocology. 4th edition. New York: McGraw Hill; 2000. p. 1053-89.
71. Norberg A, Jones AW, Hahn RG, Gabrielsson JL. Role of variability in explaining ethanol pharmacokinetics: research and forensic applications. Clin Pharmacokinet 2003;42:1-31.
72. Tallman JF, Gallager DW. The GABA-ergic system: a locus of benzodiazepine action. Annu Rev Neurosci 1985;8:21-44.
73. Costa E, Auta J, Grayson DR, Matsumoto K, Pappas GD, Zhang X, et al. GABAA receptors and benzodiazepines: a role for dendritic resident subunit mRNAs. Neuropharmacology 2002;43:925-37.
74. Mohler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther 2002;300:2-8.
75. Impagnatiello F, Pesold C, Longone P, Caruncho H, Fritschy JM, Costa E, et al. Modifications of gamma-aminobutyric acidA receptor subunit expression in rat neocortex during tolerance to diazepam. Mol Pharmacol 1996;49:822-31.
76. Charney D, Mihic S, Harris R. Hypnotics and sedatives. In: Hardman JG, Limbird LE, editors. Goodman and Gilman's the pharmacologic basis of therapeutics. 10th edition. New York: McGraw-Hill Publishing; 2001. p. 399-427.
77. Azmitia EC. Modern views on an ancient chemical: serotonin effects on cell proliferation, maturation, and apoptosis. Brain Res Bull 2001;56:413-24.
78. Sander-Bush E, Mayer SE. 5-Hydroxytryptamine (serotonin): receptor agonists and anatagonists. In: Hardman JG, editor. Goodman and Gilman's the pharmacologic basis of therapeutics. 10th edition. New York: McGraw-Hill Publishing; 2001. p. 269-90.
79. Lemberger L, Farid NA, Bergstrom RF, Wolen RL. Fluoxetine, pharmacology and physiologic disposition. Int J Obes 1987;11(Suppl 3):157-61.
80. Baldessarini R. Drugs and the treatment of psychotic disorders: depression and anxiety disorders. In: Hardman JG, editor. Goodman and Gilman's the pharmacologic basis of therapeutics. 10th edition. New York: McGraw-Hill Publishing; 2001. p. 447-83.
81. Nordeng H, Lindemann R, Perminov KV, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001;90:288-91.
82. Tenenbein M. Clinical/biophysiologic aspects of inhalant abuse. In: Sharp CW, Beauvais F, Spence R, editors. Inhalant abuse: a volitile agenda. Rockville, MD: National Institute on Drug Abuse; 1992. p. 173-80. National Institute of Drug Abuse Research Monograph 129.